LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

19.12 -2.94

Buy Sell

Overview

Share price change

24h

Current

Min

19.03

Max

19.29

Key metrics
By Trading Economics
Income	4.8M -36M
Sales	6.1M 116M
Profit margin	-30.977
Employees	1,869
EBITDA	24M -31M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+83.49% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-800M 2.2B
Previous open	22.06
Previous close	19.12

News Sentiment

By Acuity

44%

56%

128 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lut 2026, 23:53 UTC

Hot Stocks

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 lut 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 lut 2026, 17:55 UTC

Hot Stocks

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 lut 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 lut 2026, 23:33 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 21:30 UTC

Earnings

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 lut 2026, 21:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 lut 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 lut 2026, 21:17 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 lut 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 lut 2026, 21:00 UTC

Earnings

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 lut 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 lut 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 lut 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 lut 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 lut 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 lut 2026, 19:39 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 19:38 UTC

Earnings

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 lut 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 lut 2026, 18:45 UTC

Earnings

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 lut 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 lut 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 17:07 UTC

Earnings

Pemex Cuts 4Q Loss As Operating Results Improve

27 lut 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27 lut 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27 lut 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 lut 2026, 15:49 UTC

Earnings

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

83.49% upside

12 Months Forecast

Average 36.13 USD 83.49%

High 47 USD

Low 21.8 USD

Based on 6 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

128 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.